25 February 2018
News and Views
Links and Services
Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease, reports January's Inflammatory Bowel Disease.
Data regarding the effectiveness of anti-tumor necrosis factor agents for resolution of extrainte
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors